Global Information
회사소개 | 문의 | 위시리스트

세계의 종양괴사인자(TNF) 억제제 시장, 용량, 가격, 임상 파이프라인 전망

Global Tumor Necrosis Factor Inhibitors Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024

리서치사 KuicK Research
발행일 2018년 03월 상품 코드 608798
페이지 정보 영문 300 Pages
가격
US $ 2,400 ₩ 2,831,000 Unprintable PDF by E-mail (Single User License)
US $ 3,000 ₩ 3,539,000 CD-ROM
US $ 3,600 ₩ 4,247,000 Hard Copy
US $ 4,800 ₩ 5,663,000 Printable PDF by E-mail (Multi-User License)

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 종양괴사인자(TNF) 억제제 시장, 용량, 가격, 임상 파이프라인 전망 Global Tumor Necrosis Factor Inhibitors Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024
발행일 : 2018년 03월 페이지 정보 : 영문 300 Pages

세계의 종양괴사인자(TNF: Tumor Necrosis Factor) 억제제 시장에 대해 조사 분석했으며, 시장 동향, 매출·가격·용량 분석, 임상 파이프라인, 매출 예측, 시장 전망, 출시 의약품 등의 정보를 정리하여 전해드립니다.

제1장 종양괴사인자(TNF) : 개요

  • TNF란?
  • TNF의 역사와 발견

제2장 종양괴사인자(TNF)의 중요성

  • 세포 시그널링과 면역에서의 TNF
  • 암에서 TNF의 역할
  • TNF 관련·TNF 패밀리 관련 질환

제3장 종양괴사인자(TNF) 억제제의 작용기전과 치료의 발전

  • TNF와 면역반응
  • TNF 억제 : 단클론항체별

제4장 종양괴사인자(TNF) 억제제 개발 방식

  • 단클론항체 방식
  • 재조합 DNA 기술 방식

제5장 세계의 종양괴사인자 알파(TNF-α) 억제제 파이프라인 개요

제6장 세계의 종양괴사인자 알파(TNF-α) 억제제 임상 파이프라인 : 기업별, 적응증별, 상(相)별

  • 단계 불명
  • 연구
  • 전임상
  • 임상
  • 제I상
  • 제I/II상
  • 제II상
  • 제II/III상
  • 제III상
  • 신청
  • 승인완료

제7장 출시된 종양괴사인자 알파(TNF-α) 억제제 임상 분석 : 기업별, 적응증별

제8장 시판 TNF 치료제의 가격, 용량, 치료 비용 분석

  • Cimzia(Certolizumab Pegol)
  • Enbrel(Etanercept)
  • Humira( Adalimumab)
  • Otezla(Apremilast)
  • Remicade(Infliximab)
  • Simponi(Golimumab)

제9장 TNF 억제제 부문의 현재 시장 동향과 최근 발전

제10장 TNF 억제제 : 매출과 특허 분석

제11장 TNF 억제제 시장 성장 촉진요인

제12장 세계의 TNF 억제제 시장 성장 억제요인

제13장 세계의 TNF 억제제의 향후 예측과 매출 예측

제14장 경쟁 구도

  • AbbVie
  • Ablynx
  • Apogenix
  • AryoGen Biopharma
  • Bionovis
  • CASI Pharmaceuticals
  • Celltrion
  • Celgene Corporation
  • Delenex Therapeutics
  • Dexa Medica
  • EPIRUS Biopharmaceuticals
  • Janssen Biotech
  • GlaxoSmithKline
  • HanAll Biopharma
  • Intas Pharmaceuticals
  • LEO Pharma
  • LG Life Sciences
  • MedImmune
  • Momenta Pharmaceuticals
  • Novartis
  • PROBIOMED
  • Reliance Life Sciences
  • Sandoz
  • Samsung Bioepis
  • Sanofi-Aventis
  • Shanghai CP Guojian Pharmaceutical
  • Shanghai Pharmaceuticals
  • Simcere Pharmaceutical
  • Toyama Chemical
  • Tsumura
  • UCB
  • Zydus Cadila
LSH 18.03.14

“Global Tumor Necrosis Factor Inhibitors Drug Market Dosage Price & Clinical Pipeline Outlook 2024” Report Highlights:

  • Global TNF Inhibitors Market Trends
  • Key TNF Inhibitors Drug Sales, Price & Dosage Analysis
  • Global TNF Inhibitors Clinical Pipeline by Company, Indication & Phase
  • Sales Projections of Key Drugs Till 2024
  • Clinical Pipeline Data by Phase
  • TNF Inhibitors Market Future Outlook
  • Marketed Drug Clinical & Patent Insight

Tumor Necrosis Factor (TNF) is a vital protein that plays a key role in the regulation of immune cells. Several Clinical studies have proved that the level of TNF is significantly high in patients suffering from Autoimmune Diseases like Rheumatoid arthritis, Ankylosing Spondylitis and Crohn's Disease.Each of these indications have shown high prevalence globally in the past few years with million of new incidence being reported every year.

This discovery has lead pharmaceutical companies to develop therapeutics which aims at inhibiting the overexpression of TNF. TNF inhibitors, also known as Anti TNF therapeutics work by attaching to TNF receptors, thus lowering the levels of TNF in the body; resulting in prevention of inflammatory response and chronic pain. The use of TNF inhibitors in each of the above mentioned clinical conditions have been found to provide excellent therapeutic efficacy with minimal side effects, thus making them global leaders in the autoimmune disorder, pain management and inflammatory therapeutic segment.

Etanercept (Enbrel), Infliximab (Remicade), Adalimumab(Humira) , Certolizumab, and Golimumab(Simponi) are the key therapeutics that make up the global TNF inhibitors Market. Among these, Humira and Remicade have made it to the list of Blockbuster drugs of 2017 with global sales of US$ 17.6 Billion and US$ 5.9 Billion Respectively. Remicade is closely followed by another TNF inhibitor Enbrel, with global sales of US$ 5.8 Billion.

With the launch of biosimilar version of each TNF inhibitors, the global TNF inhibitors market is bound to undergo a dynamic change with respect to revenues.

Factors like patent expiration, involvement of emerging biotechnology and pharmaceutical firms, collaboration and support from regulatory authorities for easy approval has facilitated the commercialization of novel TNF inhibitors and their biosimilars.

Although the TNF inhibitors market is being flooded with wide range of TNF Biosimilars; certain therapeutics are bound to remain dominant in the global TNF inhibitors market. For instance, Despite Humira being one of the earliest therapeutic in the market, it has managed to acquire the largest market size globally. The success of Humira indicates high market potential in the newly approved therapeutics that are anticipated to enter the market soon, thus proving that the TNF inhibitor segment is here to stay.

While North America is still the Dominant market when it comes to TNF inhibitors; Analysis shows the market dominance shifting towards European and Asian regions during the forecast period. Patent Expiry of Existing TNF inhibitors, Favorable reimbursement plans, lenient drug regulation laws are few key reasons for the shift of the TNF inhibitors market towards the European and Asia Pacific Region. Further, launching of new products, advancement in scientific and technical aspect of Drug development and increasing investment in healthcare are fuelling factors that provide an optimistic forecast in the developing Asian regions like China and India.

Global Increase in elderly population and rise in the prevalence of rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease are key factors that drive the TNF inhibitors market. Studies indicate that 20% of the global population is suffering from some kind of chronic pain, with rheumatoid arthritis showing the highest prevalence. Estimated data indicates that the number of people suffering from Rheumatoid arthritis alone might rise to over 78 Million by 2040, thus ensuring exponential growth to the TNF inhibitors Market.

KuicK Research provides an in-depth analysis of the Global TNF inhibitors market with special emphasis on the global market size, market trends and dynamics, pricing and cost analysis of products and competitive landscape. KuicK Research analysis is based on extensive research from primary and secondary sources with special emphasis on market opportunities in promising regions globally ensuring an optimistic future forecast of the TNF inhibitors market.

Table of Contents

1. Tumor Necrosis Factor - An Overview

  • 1.1. Prologue to Tumor Necrosis Factor
  • 1.2. History & Discovery of Tumor Necrosis Factors

2. Significance of Tumor Necrosis Factor

  • 2.1. TNF in Cell Signaling & Immunity
    • 2.1.1. Tumor Necrosis Factor Receptor 1
    • 2.1.2. Tumor Necrosis Factor Receptor 2
  • 2.2. Role of TNF in Cancer
  • 2.3. Disease Related to TNF & Members of Its Family

3. Working Mechanism of Tumor Necrosis Factors (TNF) Inhibitors & Their Therapeutic Evolution

  • 3.1. Tumor Necrosis Factor & Immune Response
  • 3.2. Tumor Necrosis Factor Inhibition by Monoclonal Antibodies

4. Approaches Used in Development of TNF Inhibitors

  • 4.1. Monoclonal Antibody Approach
  • 4.2. Recombinant DNA Technology Approach

5. Global Tumor Necrosis Factor Alpha Inhibitors Pipeline Overview

6. Global Tumor Necrosis Factor Alpha Inhibitors Clinical Pipeline by Company, Indication & Phase

  • 6.1. Unknown
  • 6.2. Research
  • 6.3. Preclinical
  • 6.4. Clinical
  • 6.5. Phase-I
  • 6.6. Phase-I/II
  • 6.7. Phase-II
  • 6.8. Phase-II/III
  • 6.9. Phase-III
  • 6.10. Preregistration
  • 6.11. Registered

7. Marketed Global Tumor Necrosis Factor Alpha Inhibitors Clinical Insight by Company & Indication

  • 7.1. Golimumab (Shinponi, Simponi, Simponi Aria, Simponi I.V, Sympony & Symposony)
  • 7.2. Pomalidomide (Imnovid & Pomalyst)
  • 7.3. Adalimumab (Humira & Raheara)
  • 7.4. Infliximab (Remicade)
  • 7.5. Certolizumab Pegol (CIMZIA AutoClicks Prefilled Pen, Cimzia & Simziya)
  • 7.6. Apremilast (Otezla)
  • 7.7. Infliximab Biosimilar - Celltrion
  • 7.8. Lumbricus Rubellus Extract (Inflectra & Remsima)
  • 7.9. Adalimumab Biosimilar (AdaliRel & Adfrar)
  • 7.10. Infliximab Biosimilar (Infimab)
  • 7.11. Infliximab Biosimilar - Bionovis/ The Instituto Vital Brazil
  • 7.12. Adalimumab Biosimilar (Exemptia)
  • 7.13. Anti-Tumour Necrosis Factor-Alpha Antibody Oral

8. Price, Dosage & Treatment Cost Analysis of Commercially Available TNF Based Therapeutics

  • 8.1. Cimzia (Certolizumab Pegol)
  • 8.2. Enbrel (Etanercept)
    • 8.2.1. Benepali - Etanercept Biosimilar
  • 8.3. Humira ( Adalimumab)
    • 8.3.1. Amjevita - Humira Biosimilar
    • 8.3.2. Cyltezo - Second Biosimilar to Humira
  • 8.4. Otezla (Apremilast)
  • 8.5. Remicade (Infliximab)
    • 8.5.1. Remsima - Infliximab Biosimilar
    • 8.5.2. Inflectra - Infliximab Biosimilar
  • 8.6. Simponi (Golimumab)

9. Current Market Trends & Recent Advances in the TNF Inhibitors Segment

  • 9.1. Dominance of TNF Inhibitors in Global Therapeutics Market
  • 9.2. Global TNF Inhibitor Market by Indication - Market Size & Growing Opportunity
    • 9.2.1. Rheumatoid Arthritis
    • 9.2.2. Psoriasis and psoriatic arthritis (PsA)
    • 9.2.3. Crohn's Disease
    • 9.2.4. Ankylosing Spondylitis
  • 9.3. Global TNF Inhibitors Market by Region
    • 9.3.1. US
    • 9.3.2. Europe
    • 9.3.3. Asia- Pacific
    • 9.3.4. Middle East & Africa (MEA)

10. TNF Inhibitor- Sales & Patent Analysis

  • 10.1. TNF Inhibitor Market by Sales
    • 10.1.1. Cimzia
    • 10.1.2. Enbrel
    • 10.1.3. Humira
    • 10.1.4. Remicade
  • 10.2. TNF Inhibitor Market by Approvals & Patent
  • 10.3. TNF Inhibitor Biosimilar Sales Analysis

11. TNF Inhibitors Market Driving Parameters

12. Restraining Factors of the Global TNF Inhibitors Market

13. Global - TNF Inhibitors Future Forecast & Sales Projections

  • 13.1. Impact of Biosimilar ‘Benepali' on Enbrel Sales
  • 13.2. Affordable Alternatives to Humira & Their Effect on Global Humira Sales
  • 13.3. Remicade & Its Biosimilar
  • 13.4. Conclusion & Executive Summary

14. Competitive Landscape

  • 14.1. AbbVie
  • 14.2. Ablynx
  • 14.3. Apogenix
  • 14.4. AryoGen Biopharma
  • 14.5. Bionovis
  • 14.6. CASI Pharmaceuticals
  • 14.7. Celltrion
  • 14.8. Celgene Corporation
  • 14.9. Delenex Therapeutics
  • 14.10. Dexa Medica
  • 14.11. EPIRUS Biopharmaceuticals
  • 14.12. Janssen Biotech
  • 14.13. GlaxoSmithKline
  • 14.14. HanAll Biopharma
  • 14.15. Intas Pharmaceuticals
  • 14.16. LEO Pharma
  • 14.17. LG Life Sciences
  • 14.18. MedImmune
  • 14.19. Momenta Pharmaceuticals
  • 14.20. Novartis
  • 14.21. PROBIOMED
  • 14.22. Reliance Life Sciences
  • 14.23. Sandoz
  • 14.24. Samsung Bioepis
  • 14.25. Sanofi-Aventis
  • 14.26. Shanghai CP Guojian Pharmaceutical
  • 14.27. Shanghai Pharmaceuticals
  • 14.28. Simcere Pharmaceutical
  • 14.29. Toyama Chemical
  • 14.30. Tsumura
  • 14.31. UCB
  • 14.32. Zydus Cadila

List of Figures

  • Figure 1-1: Multiple Roles of TNF
  • Figure 1-2: Historical timeline of Tumor Necrosis Factor
  • Figure 1-3: Historical Timeline of Tumor Necrosis Factor Inhibitors
  • Figure 2-1: TNF Factor Types & Their Inhibition
  • Figure 2-2: Diseases Related to TNF & Its Family Members
  • Figure 3-1: General Working Mechanism of TNF Inhibitors
  • Figure 5-1: Global Tumor Necrosis Factor Alpha Inhibitors Pipeline by Phase (%), 2018 till 2024
  • Figure 5-2: Global Tumor Necrosis Factor Alpha Inhibitors Pipeline by Phase (Number), 2018 till 2024
  • Figure 5-3: Global Tumor Necrosis Factor Alpha Inhibitors Pipeline by Phase (%), 2018 till 2024
  • Figure 5-4: Global Tumor Necrosis Factor Alpha Inhibitors Pipeline by Phase (Number), 2018 till 2024
  • Figure 8-1: Cimzia - Dose for Crohn's Disease (mg/week)
  • Figure 8-2: Cimzia - Dose for Rheumatoid Arthritis (US$)
  • Figure 8-3: Cimzia - Dose for Psoriatic Arthritis (mg)
  • Figure 8-4: Cimzia - Dose for Ankolysing Spondylitis (mg)
  • Figure 8-5: Cimzia (Certolizumab Pegol) - Average Price (US$)
  • Figure 8-6: Cimzia - Treatment Cost Analysis, 2018
  • Figure 8-7: TNF inhibition by Enbrel, Working Mechanism
  • Figure 8-8: Enbrel - Dosage Forms & Strength (mg & ml)
  • Figure 8-9: Enbrel - Dosage & Frequency for Arthritis, AS & PsA (mg/Week)
  • Figure 8-10: Enbrel - Dose for Juvenile Idiopathic Arthritis (mg & mg/kg)
  • Figure 8-11: Enbrel - Subcutaneous Kit Price (US$/Unit), 2018
  • Figure 8-12: Enbrel - Prefilled Syringe Price (US$/Vial), 2018
  • Figure 8-13: Global - Enbrel Price by Region (US$)
  • Figure 8-14: Enbrel - Treatment Cost Analysis (US$/Month)
  • Figure 8-15: Enbrel - Price per QALY Gained (US$), 2018
  • Figure 8-16: Humira - Mechanism of Action
  • Figure 8-17: Humira - Dosage Analysis by Indication (mg)
  • Figure 8-18: Humira - Dosage Analysis for Crohn's Disease (mg)
  • Figure 8-19: Humira - Dose for Plaque Psoriasis (mg)
  • Figure 8-20: Humira - Subcutaneous Kit Price (US$), 2017
  • Figure 8-21: Humira - Average Treatment Cost Analysis per Month (US$), 2017
  • Figure 8-22: Otezla - Dose for Plaque Psoriasis
  • Figure 8-23: Otezla - Price Analysis (US$/Unit), 2017
  • Figure 8-24: Remicade (Infliximab)- Mode of Action
  • Figure 8-25: Remicade - Dose for Crohn's Disease (mg/kg)
  • Figure 8-26: Remicade - Dose for Rheumatoid Arthritis (mg/kg)
  • Figure 8-27: Remicade- Price Analysis for 100mg Vial (US$), 2018
  • Figure 8-28: Simponi - Availability by Concentration (mg/0.5ml)
  • Figure 8-29: Simponi - Dosage Analysis (mg)
  • Figure 8-30: Simponi - Price Analysis (US$/ml), 2018
  • Figure 9-1: Global- Therapeutics Market Segmentation by size (%)
  • Figure 9-2: Global - Rheumatoid Arthritis Prevalence (per 100,000 Individuals), 2016-2017
  • Figure 9-3: Global - Psoriasis & Psoriatic Arthritis Prevalence, 2015-2016
  • Figure 9-4: Global- Crohn's Disease Epidemiology (per 100,000 Individuals), 2012-2017
  • Figure 9-5: Global - Ankylosing Spondylitis (per 100,000 Individuals), 2018
  • Figure 9-6: US - TNF inhibitors Market by Prevalence of Indication (per 1000 Individuals) , 2017
  • Figure 9-7: Humira Cost Analysis by Region- US v/s India (US$/Vial), 2017
  • Figure 10-1: Global- Cimzia Sales (US$ Million), 2016 & 2017
  • Figure 10-2: Global - Enbrel Sales (US$ Million), 2014-2017
  • Figure 10-3: Global- Humira Sales (US$ Million), 2014-2017
  • Figure 10-4: Global- Remicade Sales (US$ Million), 2014-2017
  • Figure 10-5: Global - TNF Inhibitors Patent by Number
  • Figure 10-6: Patent Analysis - Patent Expiration by Year
  • Figure 10-7: Global - TNF Inhibitor Biosimilar Sales (US$ Million), 2015-2017
  • Figure 10-8: Global - Benepali Sales (US$ Million), 2016-2017
  • Figure 11-1: Driving Factors of the TNF Inhibitors Segment
  • Figure 12-1: Challenging Factors of the TNF Inhibitors Market
  • Figure 13-1: Global - Enbrel Sales Future Forecast (US$ Million), 2017-2024
  • Figure 13-2: Global - Humira Sales Forecast (US$ Million), 2017-2024
  • Figure 13-3: Global - Amjevita Sales Future Forecast (US$ Million), 2020 & 2024
  • Figure 13-4: Global - Remicade Future Sales Forecast (US$ Million), 2016-2024
  • Figure 13-5: Global - Blockbuster TNF Inhibitors Sales (US$ Billion), 2017
  • Figure 14-1: Ablynx - Clinical Pipeline
  • Figure 14-2: Apogenix - Clinical Pipeline
  • Figure 14-3: Casi Pharmaceutical - Clinical Pipeline
  • Figure 14-4: Celgene - Clinical Pipeline
  • Figure 14-5: EPIRUS Biopharmaceuticals - Clinical Pipeline
  • Figure 14-6: HanAll Biopharma - Clinical Pipeline
  • Figure 14-7: Novartis - Clinical Pipeline
  • Figure 14-8: Sandoz - Clinical Pipeline
  • Figure 14-9: Toyama Chemical - Clinical Pipeline
  • Figure 14-10: Zydus Cadila - Clinical Pipeline
Back to Top
전화 문의
F A Q